N-(2-Adamantan-1-yl-ethyl)-2-chloro-5-(3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-benzamide | 524712-44-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2-Adamantan-1-yl-ethyl)-2-chloro-5-(3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-benzamide
• 英文别名: N-[2-(1-adamantyl)ethyl]-2-chloro-5-(3,5-dioxo-1,2,4-triazin-2-yl)benzamide
• CAS: 524712-44-5
• 化学式: C₂₂H₂₅ClN₄O₃
• 分子量: 428.918
• InChiKey: UCHNTWMXICMHTL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  90.9
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• N-alkyl-adamantyl triazinyl benzamide derivatives
  申请人：Pfizer Inc.

  公开号：US20030144293A1

  公开（公告）日：2003-07-31

  The present invention relates to novel to N-alkyl adamantyl triazinyl benzylamide derivatives of formmula I 1 and to processs for their preparation, intermediates useful in their preparation, pharmaceutical compositions containing them, and their use in therapy. The active compounds of the present invention are useful in the treatment of inflammation, osteoarthritis, rhematoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

  本发明涉及一种新型的N-烷基金刚烷三嗪基苯甲酰胺衍生物（I1式），以及它们的制备方法、在制备中有用的中间体、含有它们的药物组合物，以及它们在治疗中的应用。本发明的活性化合物在治疗炎症、骨关节炎、类风湿性关节炎、癌症、中风或心脏病的再灌注或缺血、自身免疫性疾病和其他疾病中有用。
• N-adamantylalkyl benzamide derivates as p2x7-receptor antagonists
  申请人：Pfizer Products Inc.

  公开号：EP1310493A1

  公开（公告）日：2003-05-14

  The present invention relates to novel to N-adamantylalkyl benzylamide derivatives of formmula I and to process for their preparation, intermediates useful in their preparation, pharmaceutical compositions containing them, and their use in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

  本发明涉及形式 I 的新型 N-金刚烷基苄酰胺衍生物 及其制备工艺、用于制备它们的中间体、含有它们的药物组合物，以及它们在治疗炎症、骨关节炎、类风湿性关节炎、癌症、中风或心脏病发作中的再灌注或缺血、自身免疫性疾病和其他疾病中的用途。
• US6927219B2
  申请人：——

  公开号：US6927219B2

  公开（公告）日：2005-08-09
• [EN] N-ALKYL-ADAMANTYL DERIVATIVES AS P2X7-RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE N-ADAMANTYLALKYLE BENZAMIDE EN TANT QU'ANTAGONISTES DU RECEPTEUR P2X7
  申请人：PFIZER PROD INC

  公开号：WO2003042190A1

  公开（公告）日：2003-05-22

  The present invention relates to novel to N-alkyl adamantyl triazinyl benzylamide derivatives of formula (I) and to process for their preparation, intermediates useful in their preparation, pharmaceutical compositions containing them, and their use in the treatment of inflammation, osteoarthritis, rhematoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.